ANI Pharmaceuticals (ANIP)

[Just the facts maam]

Silvr, upon looking at, Vyndaquel's patent and data exclusivity it looks like all patents expire by 04/27/2024 however it has a patent term extension pending taking it's patent protection to 2028. All data exclusivity expires by 05/03/2026. Vyndamax on the other hand has one patent that expires in 2035, however, the rest of the patents and data exclusivity period are similar to Vyndaquel.

Sammy was listed first in their patent application, most likely the primary contributor to the invention. As one of the founding partners of Nuray Chemicals, it is difficult to believe that ANIP won't be the company that is licensed the rights to this patent. If so, ANIP should launch in 2028 maybe sooner depending on what patent data is used in their application. Nuray's patent describes a superior form of delivery over Vyndaquel. I imagine it will compete with generic competition, but in the end should be a more effective drug.

Sammy and Novitium might not even need this drug to reach his full earn-out, but it will definitely get them there by 2029, if not sooner.